Medical scientists

Three parts of your work where AI is already doing real lifting, and what stays yours.

• Compound microscope + bacterial culture1898–1940

  Compound microscope + bacterial culture (Koch's postulates era)

  Robert Koch's 1876 demonstration that Bacillus anthracis caused anthrax (proved by isolating, culturing, and reinjecting the organism) established the fundamental method of laboratory medicine: grow the agent, study it in isolation, prove causation by fulfilling postulates. The tools were the compound microscope (Zeiss objective lenses), glass culture plates (Koch's gelatin medium, later agar), and Bunsen burners for sterile technique. American medical researchers trained in German laboratories brought these methods home. Koch-trained William Welch built the first US bacteriology laboratory at Johns Hopkins in 1884; his student Simon Flexner later directed the Rockefeller Institute (1903). The microscope and the petri dish were not merely tools: they defined what a medical scientist did. Every experiment for the next decades ultimately came back to something seen under a lens or grown on a plate.

  Effect on the work

  The Koch-Pasteur bacteriological revolution created the occupation. Before 1876, "medical research" meant anatomy, physiology, and clinical observation. After 1876, it meant microbiology: a laboratory discipline requiring trained personnel. The US population of medical laboratory scientists doubled each decade from 1890 to 1940.

• Ultracentrifuge + electron microscope +…1940–1960

  Ultracentrifuge + electron microscope + radioisotope tracers

  Three instruments transformed medical research in the 1940s-1950s, each enabling a different scale of investigation. The ultracentrifuge (Svedberg, 1920s; analytical ultracentrifuge by 1940) allowed researchers to separate and characterize macromolecules by molecular weight: the first tool that could distinguish protein complexes and viruses by their physical properties. The electron microscope (commercial Siemens and RCA models by 1940) could resolve structures smaller than the light microscope: virus particles, cell organelles, and eventually DNA. Radioisotope tracers (carbon-14 became widely available after WWII from Oak Ridge National Laboratory) allowed researchers to label metabolic compounds and follow them through biological processes: the method used by Calvin to map photosynthesis (1954) and by Kornberg to trace DNA replication (1956). These tools did not merely improve existing experiments; they opened entirely new questions that defined the biological revolution of the 1950s-1970s.

• Molecular biology1953–1975

  Molecular biology: DNA double helix + Watson-Crick base pairing

  Watson and Crick's April 25, 1953 Nature paper "A Structure for Deoxyribose Nucleic Acid", hundreds of words and one diagram, reoriented all of medical research. Once the information-storage mechanism of life was understood to be a sequence of base pairs in a double helix, the program for the next decades of research became obvious: determine the sequence, understand the code, and intervene in disease at the level of DNA. The molecular biology revolution that followed created new research techniques at a remarkable rate: Meselson-Stahl DNA replication (1958); mRNA discovery (Jacob and Monod, 1961); the genetic code cracked (Nirenberg and Khorana, 1966 Nobel); restriction enzymes (Arber, Smith, Nathans, 1970 Nobel in 1978). Each advance created a new class of experiments that medical scientists could run. The paradigm shift was as profound as Koch's: before Watson-Crick, medical research studied organisms; after, it increasingly studied molecules.

• Recombinant DNA + monoclonal antibodies…1973–1995

  Recombinant DNA + monoclonal antibodies + PCR

  Three techniques in quick succession gave medical scientists the ability to engineer biology rather than merely observe it. Herbert Boyer and Stanley Cohen's 1973 experiment cut and spliced DNA from two different organisms using restriction enzymes: the first recombinant DNA experiment. Three years later, Boyer co-founded Genentech, the first company built entirely on recombinant DNA, which produced recombinant human insulin in 1982: the first recombinant pharmaceutical approved for human use. Köhler and Milstein's 1975 hybridoma technique (1984 Nobel) produced monoclonal antibodies: proteins precisely targeted to a single molecular epitope, which became the foundation of modern immunotherapy. Kary Mullis's polymerase chain reaction (PCR, 1983, 1993 Nobel) amplified trace quantities of DNA a billion-fold, making DNA analysis routine and launching diagnostics, forensics, and evolutionary biology as population-scale sciences. Together these three tools turned the hypothetical promises of molecular biology into commercial biotechnology, and created the pharmaceutical and biotech research employment that now accounts for over a third of the 19-1042 workforce.

  Effect on the work

  Genentech's 1980 IPO (double the offering price within minutes) launched the US biotech industry. By 1990 there were more than a thousand US biotech companies; by 2000 over 1,500. Each required medical scientists. The biotech sector transformed the employment geography of the occupation: from almost entirely academic + government pre-1973, to roughly one-third industry by 2000.

• Human Genome Project → next-generation…1990–2010

  Human Genome Project → next-generation sequencing

  The Human Genome Project, launched October 1990 as an international collaboration co-led by the NIH and the DOE, set out to sequence all base pairs of the human genome. It completed its first working draft in June 2000, declared completion in April 2003, and at an eventual cost of approximately $3 billion established the reference sequence against which all subsequent genomics research is calibrated. The HGP's real legacy was not the sequence itself: it was the bioinformatics and sequencing-technology infrastructure built to produce it. Next-generation sequencing (Solexa / Illumina, commercially available from 2007) then cut the cost of a whole human genome by orders of magnitude, the fastest sustained decline in the cost of any scientific instrument in history, and it created an entirely new sub-discipline of medical scientists (computational biologists, bioinformaticians, and genomic epidemiologists) working at the intersection of biology and data science.

  Effect on the work

  The NIH budget doubled between 2000 and 2003 during the HGP completion and post-genomics expansion. This drove a commensurate expansion in funded research positions. The sequencing-cost collapse created a second wave of hiring as genomic analysis became accessible to every medical school, not just the five major sequencing centers.

• AlphaFold v1→v2→v32018–2024

  AlphaFold v1→v2→v3: protein-structure prediction at scale

  Protein folding had been the central unsolved problem in structural biology for decades: given a protein's amino acid sequence, predict its three-dimensional structure. The structure determines function; the function determines mechanism; the mechanism determines whether a drug can intervene. The computational solution arrived at the CASP13 competition in December 2018 when DeepMind's AlphaFold v1 outperformed every other method. At CASP14 in November 2020, AlphaFold 2 achieved a median accuracy of less than one angstrom: essentially solving the problem to within the precision limits of experimental crystallography. The July 2021 Nature paper by John Jumper, Demis Hassabis, and many co-authors described the architecture; in 2022 DeepMind released predictions for the entire human proteome (tens of thousands of proteins) and then for 200 million proteins across all sequenced organisms: freely available. AlphaFold 3 (May 2024) extended prediction to protein-ligand and protein-nucleic acid complexes, enabling drug-binding-site prediction. In October 2024, Jumper and Hassabis received the Nobel Prize in Chemistry for the work. For medical scientists, AlphaFold eliminated what had previously been a years-long bottleneck: you can now download a high-confidence structure prediction in seconds for a target that would have required several years of X-ray crystallography or cryo-EM work. The effect is not job elimination: it is a profound acceleration of the hypothesis-generation stage of drug discovery.

  Effect on the work

  DeepMind reports millions of researchers across more than a hundred countries have used AlphaFold since 2022. AI drug discovery companies built on AlphaFold and related tools (Recursion Pharmaceuticals [IPO 2021], Insitro, Schrödinger, Insilico Medicine) collectively raised over $3B in venture capital between 2020 and 2024, creating a new category of computational medical scientist roles at the intersection of ML and structural biology.

• mRNA platform + AI-accelerated drug dis…2020–present

  mRNA platform + AI-accelerated drug discovery + LLM research tools

  Three overlapping technological platforms reshaped what a medical scientist does in the 2020s. First: the mRNA platform validated at scale by COVID vaccines. Katalin Karikó and Drew Weissman's 2005 discovery that chemically modified nucleoside bases could suppress the immune response to synthetic mRNA, work for which they received the 2023 Nobel Prize in Medicine, had languished for a decade before Moderna and BioNTech used it to design vaccine candidates within hours of the SARS-CoV-2 sequence being published (January 11, 2020). The Moderna vaccine received FDA Emergency Use Authorization on December 18, 2020; BioNTech-Pfizer on December 11, 2020: each under a year from sequence to authorization, shattering the previous record. Billions of COVID-19 doses were administered globally. The platform is now in clinical trials for cancer, influenza, HIV, and RSV vaccines. Second: AI-accelerated drug discovery (Recursion, Insitro, Schrödinger) applies machine learning to high-content screening, ADMET prediction, and hit-to-lead optimization, compressing steps that previously took several years into months. Third: LLM-based research tools (Elicit, Consensus, Scite, Semantic Scholar) are reshaping the literature-review and hypothesis-generation phases of the job. A medical scientist can now run a structured systematic literature review in hours that previously took months.

  Effect on the work

  The mRNA validation created a commercial-scale platform requiring an entirely new workforce: mRNA design scientists, lipid nanoparticle formulation chemists, and process development researchers. BioNTech grew in the same period. LLM tools are restructuring time allocation within the role but have not reduced headcount: they have shifted time from rote literature processing toward hypothesis testing and experimental design.